Phase IV Clinical Trial of Nimotuzumab in the Treatment of Nasopharyngeal Carcinoma
Phase of Trial: Phase IV
Latest Information Update: 05 Dec 2017
At a glance
- Drugs Nimotuzumab (Primary)
- Indications Nasopharyngeal cancer
- Focus Adverse reactions
- Sponsors Biotech Pharmaceutical
- 18 Aug 2015 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017, as reported by ClinicalTrials.gov.
- 18 Aug 2015 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2017, as reported by ClinicalTrials.gov.
- 21 Nov 2014 New trial record